Aspaveli is indicated as monotherapy in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH) who have haemolytic anaemia.1
Ongoing anaemia
PNH is a rare and potentially life-threatening disease characterised by the complement-mediated destruction of red blood cells, known as haemolysis.3,4
PNH results in a variety of complications, including anaemia, thrombosis and fatigue.3,4
Two types of haemolysis occur in PNH:
Discover the indicators of ongoing EVH
A combination of these haematologic indicators may suggest EVH:5,6
- Below normal levels of Hb
- Normal or slightly elevated LDH
- Elevated ARC and/or elevated levels of bilirubin
References
1. Aspaveli (pegcetacoplan) Summary of Product Characteristics 08/2024. 2. Hillmen P, Szer J, Weitz IC, et al. N Engl J Med. 2021;384:1028–1037. 3. Hill A, DeZern A, Kinoshita T, et al. Nat Rev Dis Primers. 2017;3(18):17028. 4. Risitano AM and Peffault de Latour R. BJH. 2022;196:288–303. 5. Hill A, Rother RP, Arnold L, et al. Haematologica. 2010;95(4):567–573. 6. Brodsky RA. Blood. 2014;124(18):2804–2811.